Senhwa Biosciences Inc (生華科) yesterday said it has partnered with the US National Institutes of Health (NIH) to evaluate the efficacy of a new drug, dubbed Silmitasertib, for treatment of COVID-19.
The drug, developed by Senhwa Biosciences to treat cancers, such as bile duct cancer, medulloblastoma and pediatric brain tumor, showed promise in human tests to curb the ribonucleic acid (RNA) virus from proliferating.
“With the attribute, the drug is expected to help combat the novel coronavirus. We have not tested the drug on patients with COVID-19 in Taiwan, but the US NIH, looking forward to the drug’s efficacy, will run some trials in the US,” Senhwa Biosciences CEO Soong Tai-sen (宋台生) said by telephone.
The company would offer the drug for free to the US agency during the tests, but it is difficult to forecast when the trials would be completed, Soong said.
The New Taipei City-based firm has no intention of running human trials for COVID-19 treatment in Taiwan, as it has put all of its resources into its clinical trials on cancer treatment, but it is willing to partner with other companies and provide its drugs for free, Soong said.
The University of California San Francisco’s Quantitative Biosciences Institute last month identified 69 drugs or experimental compounds that might be effective in treating COVID-19, including the Silmitasertib, Soong said.
Silmitasertib could promote the formation of street granules by disrupting casein kinase 2, a protein kinase that performs diverse functions related to cell survival, thus preventing viruses from gaining ingredients such as nucleic acids to create a new virus, Soong said.
“Silmitasertib offers two advantages. First, its safety has been proven during our previous tests on about 300 people for cancer treatment. And second, we have about 120kg of Simitasertib in storage in the US, which would be convenient in terms of delivery to the NIH,” he said.
Given that Silmitasertib, unlike other potential new drugs under testing for COVID-19, such as remdesivir, does not directly attack the coronavirus or reduce lung damage, it is more likely to be used as a adjuvant drug, Soong said.
However, whether it would be effective and how it would be used with other medication would be determined by the NIH, Soong said.
Silmitasertib marks the only CK2 inhibitor present in clinical trials, he said.
The drug is undergoing a few human tests, including a Phase II trial for bile duct cancer in Taiwan, the US and South Korea, a Phase II clinical trial for medulloblastoma, sponsored by the National Institute of Health-Cancer Therapy Evaluation Program and the Pediatric Brain Tumor Consortium, and a Phase I study for advanced basal cell carcinoma, it said.
TRADE WAR: Tariffs should also apply to any goods that pass through the new Beijing-funded port in Chancay, Peru, an adviser to US president-elect Donald Trump said A veteran adviser to US president-elect Donald Trump is proposing that the 60 percent tariffs that Trump vowed to impose on Chinese goods also apply to goods from any country that pass through a new port that Beijing has built in Peru. The duties should apply to goods from China or countries in South America that pass through the new deep-water port Chancay, a town 60km north of Lima, said Mauricio Claver-Carone, an adviser to the Trump transition team who served as senior director for the western hemisphere on the White House National Security Council in his first administration. “Any product going
TECH SECURITY: The deal assures that ‘some of the most sought-after technology on the planet’ returns to the US, US Secretary of Commerce Gina Raimondo said The administration of US President Joe Biden finalized its CHIPS Act incentive awards for Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), marking a major milestone for a program meant to bring semiconductor production back to US soil. TSMC would get US$6.6 billion in grants as part of the contract, the US Department of Commerce said in a statement yesterday. Though the amount was disclosed earlier this year as part of a preliminary agreement, the deal is now legally binding — making it the first major CHIPS Act award to reach this stage. The chipmaker, which is also taking up to US$5 billion
High above the sparkling surface of the Athens coastline, the cranes for building the 50-floor luxury tower centerpiece of Greece’s future “smart city” look out over the Saronic Gulf. At their feet, construction machinery stirs up dust. Its backers say the 8 billion euro (US$8.43 billion) project financed by private funds is a symbol of Greece’s renaissance after the years of financial stagnation that saw investors flee the country. However, critics see it more as a future “ghetto for the rich.” It is hard to imagine that 10km from the Acropolis, a new city “three times the size of Monaco”
STRUGGLING BUSINESS: South Korea’s biggest company and semiconductor manufacturer’s buyback fuels concerns that it could be missing out on the AI boom Samsung Electronics Co plans to buy back about 10 trillion won (US$7.2 billion) of its own stock over the next year, putting in motion one of the larger shareholder return programs in its history. South Korea’s biggest company would repurchase the stock in stages over the coming 12 months, it said in a regulatory filing on Friday. As a first step, it would buy back about 3 trillion won of paper starting today up until February next year, all of which it would cancel. The board would deliberate on how best to effect the remaining 7 trillion won of buybacks. The move
RSS